HomeCompareHLOSF vs YUM

HLOSF vs YUM: Dividend Comparison 2026

HLOSF yields 90.91% · YUM yields 1.85%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 HLOSF wins by $2.56M in total portfolio value
10 years
HLOSF
HLOSF
● Live price
90.91%
Share price
$2.20
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$2.67M
Annual income
$842,999.04
Full HLOSF calculator →
YUM
YUM
● Live price
1.85%
Share price
$155.48
Annual div
$2.88
5Y div CAGR
51.4%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$107.0K
Annual income
$39,957.33
Full YUM calculator →

Portfolio growth — HLOSF vs YUM

📍 HLOSF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodHLOSFYUM
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, HLOSF + YUM cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
HLOSF pays
YUM pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

HLOSF
Annual income on $10K today (after 15% tax)
$7,727.27/yr
After 10yr DRIP, annual income (after tax)
$716,549.18/yr
YUM
Annual income on $10K today (after 15% tax)
$157.45/yr
After 10yr DRIP, annual income (after tax)
$33,963.73/yr
At 15% tax rate, HLOSF beats the other by $682,585.45/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of HLOSF + YUM for your $10,000?

HLOSF: 50%YUM: 50%
100% YUM50/50100% HLOSF
Portfolio after 10yr
$1.39M
Annual income
$441,478.18/yr
Blended yield
31.83%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on YUM right now

HLOSF
Analyst Ratings
2
Buy
Consensus: Buy
Altman Z
1.9
Piotroski
2/9
YUM
Analyst Ratings
18
Buy
30
Hold
3
Sell
Consensus: Hold
Price Target
$173.15
+11.4% upside vs current
Range: $158.00 — $190.00
Altman Z
2.6
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

HLOSF buys
0
YUM buys
0
No recent congressional trades found for HLOSF or YUM in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricHLOSFYUM
Forward yield90.91%1.85%
Annual dividend / share$2.00$2.88
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%51.4%
Portfolio after 10y$2.67M$107.0K
Annual income after 10y$842,999.04$39,957.33
Total dividends collected$2.36M$80.4K
Payment frequencyquarterlyquarterly
SectorStockConsumer Discretionary
Analyst consensusBuyHold

Year-by-year: HLOSF vs YUM ($10,000, DRIP)

YearHLOSF PortfolioHLOSF Income/yrYUM PortfolioYUM Income/yrGap
1← crossover$19,791$9,090.91$10,980$280.44+$8.8KHLOSF
2$37,991$16,814.71$12,185$435.72+$25.8KHLOSF
3$70,817$30,166.17$13,722$684.14+$57.1KHLOSF
4$128,326$52,552.16$15,773$1,090.14+$112.6KHLOSF
5$226,308$88,999.24$18,650$1,773.02+$207.7KHLOSF
6$388,835$146,685.82$22,921$2,966.37+$365.9KHLOSF
7$651,597$235,543.05$29,685$5,158.69+$621.9KHLOSF
8$1,066,101$368,892.48$41,216$9,453.02+$1.02MHLOSF
9$1,704,801$564,073.19$62,672$18,571.31+$1.64MHLOSF
10$2,667,136$842,999.04$107,016$39,957.33+$2.56MHLOSF

HLOSF vs YUM: Complete Analysis 2026

HLOSFStock

Healios K.K. engages in the research and development, manufacture, and sale of cell therapy and regenerative medicine products in Japan, Europe, and the United States. The company is also developing cellular and tissue-based products comprising HLCR011 and HLCR012 that are iPSC regenerative medicines for the treatment of age-related macular degeneration; HLCL041, an iPSC regenerative medicine for the treatment of metabolic liver disease; and HLCM051, a regenerative medicine for treatment of ischemic stroke and acute respiratory distress syndrome, as well as HLCN061 for treating solid tumors. Healios K.K. has a joint research agreement with the Hyogo Medical University on cancer immunotherapies for mesothelioma using eNK cells. The company was formerly known as Retina Institute Japan, K.K. and changed its name to Healios K.K. in September 2013. Healios K.K. was incorporated in 2011 and is headquartered in Tokyo, Japan.

Full HLOSF Calculator →

YUMConsumer Discretionary

YUM! Brands, Inc., together with its subsidiaries, develops, operates, and franchises quick service restaurants worldwide. It operates through four segments: the KFC Division, the Taco Bell Division, the Pizza Hut Division, and the Habit Burger Grill Division. The company operates restaurants under the KFC, Pizza Hut, Taco Bell, and The Habit Burger Grill brands, which specialize in chicken, pizza, made-to-order chargrilled burgers, sandwiches, Mexican-style food categories, and other food products. As of December 31, 2021, it had 26,934 KFC units; 18,381 Pizza Hut units; 7,791 Taco Bell units; and 318 The Habit Burger Grill units in approximately 157 countries and territories. The company was formerly known as TRICON Global Restaurants, Inc. and changed its name to YUM! Brands, Inc. in May 2002. YUM! Brands, Inc. was incorporated in 1997 and is headquartered in Louisville, Kentucky.

Full YUM Calculator →
📬

Get this HLOSF vs YUM comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

HLOSF vs SCHDHLOSF vs JEPIHLOSF vs OHLOSF vs KOHLOSF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.